Search research articles
Contact Us
Filters
Showing results (361-370 of 635) with videos related to
Page
of 64
Sort By:
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
American Heart Journal
|
December 18, 2002
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
Debabrata Mukherjee, Kenneth W Mahaffey, David J Moliterno, et al.
European Heart Journal
|
November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
Richard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
Circulation
|
January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial
Shaun G Goodman, Robert Clare, Karen S Pieper, et al.
American Heart Journal
|
September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
J Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
Frontiers in Digital Health
|
July 9, 2025
Retention and characteristics associated with remote questionnaire completion in a general population cohort study: the project baseline health study
Megan K Carroll, Safa Faheem, Jean Bouteiller, et al.
European Heart Journal. Acute Cardiovascular Care
|
February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial
Ralf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
The American Journal of Cardiology
|
September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Diabetes, Obesity & Metabolism
|
May 19, 2022
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Chao Li, Jie Yu, Carinna Hockham, et al.
Page
of 64
Search research articles
Search
Showing results (361-370 of 635) with videos related to
Sort By:
Page
of 64
Journal of the American Heart Association
|
June 16, 2017
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial
George C Leef, Anne S Hellkamp, Manesh R Patel, et al.
Lancet (London, England)
|
March 10, 2015
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jeffrey B Washam, Susanna R Stevens, Yuliya Lokhnygina, et al.
American Heart Journal
|
December 18, 2002
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
Debabrata Mukherjee, Kenneth W Mahaffey, David J Moliterno, et al.
European Heart Journal
|
November 18, 2011
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial
Richard C Becker, Jean Pierre Bassand, Andrzej Budaj, et al.
Circulation
|
January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial
Shaun G Goodman, Robert Clare, Karen S Pieper, et al.
American Heart Journal
|
September 20, 2020
CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial
J Antonio Gutierrez, Gretchen M Heizer, W Schuyler Jones, et al.
Frontiers in Digital Health
|
July 9, 2025
Retention and characteristics associated with remote questionnaire completion in a general population cohort study: the project baseline health study
Megan K Carroll, Safa Faheem, Jean Bouteiller, et al.
European Heart Journal. Acute Cardiovascular Care
|
February 21, 2016
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial
Ralf E Harskamp, Robert M Clare, Giuseppe Ambrosio, et al.
The American Journal of Cardiology
|
September 10, 2017
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
Sean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Diabetes, Obesity & Metabolism
|
May 19, 2022
Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis
Chao Li, Jie Yu, Carinna Hockham, et al.
Page
of 64